EE416 Cost-Effectiveness of Pembrolizumab Monotherapy for First-Line Treatment in Adult Patients with Microsatellite Instability High/Mismatch Repair-Deficient Metastatic Colorectal Cancer From a French Perspective

R Aguiar-Ibáñez,L Cagnan,L Bensimon,C Mamane,E Lebbink,C Crossan,D Tougeron,C De La Fouchardière,M Amonkar

doi:10.1016/j.jval.2022.09.662

EE416 Cost-Effectiveness of Pembrolizumab Monotherapy for First-Line Treatment in Adult Patients with Microsatellite Instability High/Mismatch Repair-Deficient Metastatic Colorectal Cancer From a French Perspective

R Aguiar-Ibáñez, L Cagnan + Show 7 more

Open Access

https://doi.org/10.1016/j.jval.2022.09.662

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Dec 1, 2022
License type: publisher-specific-oa

Affiliation: University of Poitiers, Centre Hospitalier Universitaire de Poitiers, MSD (United States)

#Treatment In Adult Patients #Repair-deficient Metastatic Colorectal Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

To assess the cost-effectiveness of pembrolizumab vs. standard-of-care (SoC) treatments for first-line treatment in adult patients with microsatellite instability high (MSI-H)/mismatch repair-deficient (dMMR) unresectable or metastatic colorectal (mCRC) cancer in France.

Full Text